Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Roche to Dr. Reddy's: Back off Boniva
Roche has no intention of letting Boniva go gently into that generic night. On the heels of a patent-infringement suit against Teva last week, Roche has sued Dr. Reddy's Laboratories over the osteoporosis drug. And this after acting against Boniva copycats from Apotex and Mutual Pharmaceutical in recent weeks.
Dr. Reddy's has filed for FDA approval for its version of Boniva, but Roche claims the drug is covered by one patent or another through 2023.
- read this article from India Infoline
Related Articles:
Roche, Teva square off in Boniva patent fight. Report
Injectable Boniva approved. Report
Researchers tout once-monthly Boniva data. Report
Roche, GSK outline head-to-head trial of Boniva, Fosamax. Report
Be the first to comment
More stories about Teva Pharmaceutical Sun Pharmaceuticals Roche lawsuit Generic drugs FDA approval Eli Lilly ADHD
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
